The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Platinum(iv) anticancer prodrugs – hypotheses and facts
Abstract
Do we really know how “dual action” Pt(iv) work?
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
Wang, C.-Y., Mayo, M. W., & Baldwin, A. S. (1996) · Science · doi:10.1126/science.274.5288.784 · Cited by 2,617
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Platinum(IV) antitumour compounds: their bioinorganic chemistry
Hall, M. D., & Hambley, T. W. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00026-7 · Cited by 622
Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery
Zheng, Y.-R., Suntharalingam, K., Johnstone, T. C., Yoo, H., Lin, W., Brooks, J. G., & Lippard, S. J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5038269 · Cited by 440
What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 370
Self-citationMitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
Dhar, S., & Lippard, S. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912276106 · Cited by 369
Ang, W. H., Khalaila, I., Allardyce, C. S., Juillerat-Jeanneret, L., & Dyson, P. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0432618 · Cited by 314
Barnes, K. R., Kutikov, A., & Lippard, S. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.024 · Cited by 263
The Prodrug Platin‐A: Simultaneous Release of Cisplatin and Aspirin
Pathak, R. K., Marrache, S., Choi, J. H., Berding, T. B., & Dhar, S. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201308899 · Cited by 255
Giandomenico, C. M., Abrams, M. J., Murrer, B. A., Vollano, J. F., Rheinheimer, M. I., Wyer, S. B., Bossard, G. E., & Higgins, J. D. (1995) · Inorganic Chemistry · doi:10.1021/ic00109a004 · Cited by 248
Kim, A. J., Shi, Y., Austin, R. C., & Werstuck, G. H. (2005) · Journal of Cell Science · doi:10.1242/jcs.01562 · Cited by 233
Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review
Pinzani, V., Bressolle, F., Johanne Haug, I., Galtier, M., Blayac, J. P., & Balm�s, P. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686277 · Cited by 217
Clinical Pharmacokinetics and Administration of Established Platinum Drugs
O??Dwyer, P. J., Stevenson, J. P., & Johnson, S. W. (2000) · Drugs · doi:10.2165/00003495-200059004-00003 · Cited by 217
Sodium valproate inhibits production of TNF-α and IL-6 and activation of NF-κB
Ichiyama, T., Okada, K., Lipton, J. M., Matsubara, T., Hayashi, T., & Furukawa, S. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02439-7 · Cited by 196
Zhang, J. Z., Wexselblatt, E., Hambley, T. W., & Gibson, D. (2012) · Chem. Commun. · doi:10.1039/c1cc16647f · Cited by 190
Self-citationRaveendran, R., Braude, J. P., Wexselblatt, E., Novohradsky, V., Stuchlikova, O., Brabec, V., Gandin, V., & Gibson, D. (2016) · Chemical Science · doi:10.1039/c5sc04205d · Cited by 183
Self-citationThe ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells
Cheng, Q., Shi, H., Wang, H., Min, Y., Wang, J., & Liu, Y. (2014) · Chem. Commun. · doi:10.1039/c4cc00419a · Cited by 170
Histone deacetylase inhibitors in cancer therapy
Lee, M.-J., Kim, Y. S., Kummar, S., Giaccone, G., & Trepel, J. B. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283127095 · Cited by 128
Conjugate of Pt(IV)–Histone Deacetylase Inhibitor as a Prodrug for Cancer Chemotherapy
Yang, J. J., Sun, X., Mao, W., Sui, M., Tang, J., & Shen, Y. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200597r · Cited by 127
Valproate induces DNA demethylation in nuclear extracts from adult mouse brain
Dong, E., Chen, Y., Gavin, D. P., Grayson, D., & Guidotti, A. (2010) · Epigenetics · doi:10.4161/epi.5.8.13053 · Cited by 114
Ang, W. H., Pilet, S., Scopelliti, R., Bussy, F., Juillerat‐Jeanneret, L., & Dyson, P. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0506468 · Cited by 113
Reduction ofcis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by Aqueous Extracts of Cancer Cells
Nemirovski, A., Kasherman, Y., Ardeli‐Tzaraf, Y., & Gibson, D. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070740j · Cited by 113
Self-citationConjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance
Neumann, W., Crews, B. C., Sárosi, M. B., Daniel, C. M., Ghebreselasie, K., Scholz, M., Marnett, L. J., & Hey‐Hawkins, E. (2014) · ChemMedChem · doi:10.1002/cmdc.201402353 · Cited by 111
Pineau, T., Hudgins, W. R., Liu, L., Chen, L., Sher, T., Gonzalez, F. J., & Samid, D. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00340-1 · Cited by 110
Samid, D., Ram, Z., Hudgins, W. R., Shack, S., Liu, L., Walbridge, S., Oldfield, E. H., & Myers, C. E. (1994) · PubMed · Cited by 106
Ma, L., Ma, R., Wang, Y., Zhu, X. A., Zhang, J., Chan, H. C., Chen, X., Zhang, W., Chiu, S.-K., & Zhu, G. (2015) · Chemical Communications · doi:10.1039/c4cc10409a · Cited by 100
Mitaplatin Increases Sensitivity of Tumor Cells to Cisplatin by Inducing Mitochondrial Dysfunction
Xue, X., You, S., Zhang, Q., Wu, Y. F., Zou, G.-Z., Wang, P. C., Zhao, Y.-L., Xu, Y., Jia, L., Zhang, X., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200571k · Cited by 99
Chen, C. K. J., Zhang, J., Aitken, J. B., & Hambley, T. W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401218n · Cited by 99
Nanoparticle Encapsulation of Mitaplatin and the Effect Thereof onIn VivoProperties
Johnstone, T. C., Kulak, N., Pridgen, E. M., Farokhzad, O. C., Langer, R., & Lippard, S. J. (2013) · ACS Nano · doi:10.1021/nn401905g · Cited by 96
Wexselblatt, E., Yavin, E., & Gibson, D. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201300640 · Cited by 92
Self-citationShort-Chain HDAC Inhibitors Differentially Affect Vertebrate Development and Neuronal Chromatin
Fass, D. M., Shah, R. R., Ghosh, B., Hennig, K. M., Norton, S., Zhao, W., Reis, S. A., Klein, P. S., Mazitschek, R., Maglathlin, R. L., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1001954 · Cited by 90
Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity
Chin, C. F., Wong, D. Y. Q., Jothibasu, R., & Ang, W. H. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611798040778 · Cited by 80
Massaguer, A., González-Cantó, A., Escribano, E., Barrabés, S., Artigas, G., Moreno, V., & Marchán, V. (2014) · Dalton Transactions · doi:10.1039/c4dt02710h · Cited by 79
Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery
Pichler, V., Mayr, J., Heffeter, P., Dömötör, O., Enyedy, E. A., Hermann, G., Groza, D., Köllensperger, G., Galanksi, M., Berger, W., et al. (2013) · Chemical Communications · doi:10.1039/c3cc39258a · Cited by 79
Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands
Novohradský, V., Zerzánková, L., Štěpánková, J., Vrána, O., Raveendran, R., Gibson, D., Kašpárková, J., & Brabec, V. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.07.004 · Cited by 77
Self-citationNeumann, W., Crews, B. C., Marnett, L. J., & Hey‐Hawkins, E. (2014) · ChemMedChem · doi:10.1002/cmdc.201402074 · Cited by 76
Alessio, M., Zanellato, I., Bonarrigo, I., Gabano, E., Ravera, M., & Osella, D. (2013) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2013.09.003 · Cited by 73
Solid-phase synthesis of oxaliplatin–TATpeptide bioconjugates
Abramkin, S. A., Valiahdi, S. M., Jakupec, M. A., et al. (2012) · Dalton Transactions · doi:10.1039/c2dt12024k · Cited by 69
Zajac, J., Kostrhunová, H., Novohradský, V., Vrána, O., Raveendran, R., Gibson, D., Kašpárková, J., & Brabec, V. (2015) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2015.12.003 · Cited by 60
Self-citationJohansson, K., Ito, M., Schophuizen, C. M. S., Thengumtharayil, S. M., Heuser, V. D., Zhang, J., Shimoji, M., Vahter, M., Ang, W. H., Dyson, P. J., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2000692 · Cited by 57
Burkitt, K., & Ljungman, M. E. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-24 · Cited by 57
Valproate-dependent transcriptional regulation of GLAST/EAAT1 expression: Involvement of Ying-Yang 1
Aguirre, G., Rosas‐Madrigal, S., López‐Bayghen, E., & Ortega, A. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.01.015 · Cited by 41
Reithofer, M. R., Valiahdi, S. M., Galanski, M. S., Jakupec, M. A., Arion, V. B., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890197 · Cited by 41
Evaluation of Platinum–Ethacrynic Acid Conjugates in the Treatment of Mesothelioma
Zanellato, I., Bonarrigo, I., Sardi, M., Alessio, M., Gabano, E., Ravera, M., & Osella, D. (2011) · ChemMedChem · doi:10.1002/cmdc.201100426 · Cited by 36
Kašpárková, J., Thibault, T., Kostrhunová, H., Štěpánková, J., Vojtı́šková, M., Muchová, T. R., Midoux, P., Malinge, J., & Brabec, V. (2014) · FEBS Journal · doi:10.1111/febs.12711 · Cited by 18
Phenylbutyrate inhibits homologous recombination induced by camptothecin and methyl methanesulfonate
Kaiser, G. S., Germann, S. M., Westergaard, T., & Lisby, M. (2011) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2011.05.016 · Cited by 14
Cited by
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Classification of Metal-Based Drugs according to Their Mechanisms of Action
Boros, E., Dyson, P. J., & Gasser, G. (2020) · Chem · doi:10.1016/j.chempr.2019.10.013 · Cited by 437
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Yin, X., Zhuang, Y., Song, H., Xu, Y., Zhang, F., Cui, J., Zhao, L., Yu, Y., Zhang, Q., Ye, J., et al. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.11.002 · Cited by 9
Metadata
- Authors
- Gibson, D.
- Venue
- Dalton Transactions
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2016
- Volume
- 45
- Issue
- 33
- Pages
- 12983-12991
- ISSN
- 1477-9226 (ISSN-L)
- 1477-9234
- OpenAlex
- W2401279888
- Cited by
- 286
- References
- 50
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.